Is There an Increased Cancer Risk Associated With the Use of Angiotensin Receptor Blockers and Should It Affect Current Prescribing?

Journal of Clinical Hypertension

Volumn 13, Issue 2, 2011, Pages 131-132

  Cohen, Debbie L ^a   Townsend, Raymond R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; LOSARTAN; RAMIPRIL; TELMISARTAN;

ANTIHYPERTENSIVE THERAPY; CANCER RISK; CARCINOGENICITY; CHRONIC KIDNEY DISEASE; DRUG SAFETY; FOLLOW UP; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY ARTERY STENOSIS; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; NOTE; PREGNANT WOMAN; PRESCRIPTION; PRIORITY JOURNAL; STROKE;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS;

EID: 79251545202     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2010.00403.x     Document Type: Note

References (12)

1. Sipahi I, Debanne SM, Rowland DY, et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11(7):627-636.
2. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab. 2005;16(7):293-299.
3. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386):759-766.
4. ONTARGET Investigators. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-1559.
5. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372(9644):1174-1183.
6. Diener HC, Sacco RL, Yusuf S, et al. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008;7(10):875-884.
7. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003.
8. Armstrong B, Stevens N, Doll R. Retrospective study of the association between use of rauwolfia derivatives and breast cancer in English women. Lancet. 1974;2(7882):672-675.
9. Grossman E, Messerli FH, Goldbourt U. Does diuretic therapy increase the risk of renal cell carcinoma? Am J Cardiol. 1999;83(7):1090-1093.
10. Grossman E, Messerli FH, Goldbourt U. Carcinogenicity of antihypertensive therapy. Curr Hypertens Rep. 2002;4(3):195-201.
11. Pahor M, Furberg CD. Is the use of some calcium antagonists linked to cancer? Evidence from recent observational studies. Drugs Aging. 1998;13(2):99-108.
12. Fitzpatrick AL, Daling JR, Furberg CD, et al. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer. 1997;80(8):1438-1447.